3 Growth Greats For 2016 And Beyond! GlaxoSmithKline plc, Prudential plc & Marks and Spencer Group Plc

Royston Wild looks at the earnings potential of GlaxoSmithKline plc (LON: GSK), Prudential plc (LON: PRU) and Marks and Spencer Group Plc (LON: MKS).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at three firms with terrific long-term prospects.

Insurer on the up

Life insurance mammoth Prudential (LSE: PRU) has long been a reliable selection for those seeking chunky earnings growth year after year. The company has seen the bottom line swell at a compound annual growth rate of 11.7% during the past five years alone, and the City expects this terrific momentum to continue in the years ahead.

And with good reason — the London company has proved itself extremely effective at adapting its product ranges to to key demographic, legislative and technological changes, while its decision to expand its tentacles in Asia is also paying off handsomely. Prudential saw new business profit from this region gallop 24% higher between January and September, to £976m.

The number crunchers expect Prudential to enjoy earnings growth of 14% in 2015 and 9% next year. Consequently the business is currently dealing on a very attractive P/E ratio of 12.4 times for 2016, comfortably below the value watermark of 15 times.

Retailer poised to roar

Like Prudential, I believe that Marks & Spencer (LSE: GSK) is also a great way to tap into the huge potential of emerging markets.

Sure, the retailer may have slowed planned store openings for the next few years in light of recent macroeconomic turbulence — ‘Marks and Sparks’ had planned to open 250 new outlets between 2014 and 2017. But a more measured approach to international expansion should still deliver chunky returns, in my opinion.

Indeed, Marks & Spencer has targeted the high-growth areas of China and India as the cornerstone to overseas expansion, and is taking a multi-channel approach to unlock the value created by stampeding consumer spending power in the coming years, particularly online.

And with demand for Marks & Spencer’s premium food items steadily powering group sales, too, the City expects the business to record earnings expansion of 8% and 7% in the years to March 2016 and 2017 respectively. A subsequent P/E rating of 14 times for the current period makes the High Street giant great value for money, in my opinion.

Pharma giant on the charge

Pills play GlaxoSmithKline (LSE: GSK) has been a long-running casualty of the ‘patent wars’ that has smashed revenues at the world’s biggest medicine manufacturers. The Brentford business has seen earnings fall in three of the past four years, and a further dip — this time by a chunky 20% — is anticipated for 2015.

But the tide is gradually turning at GlaxoSmithKline thanks to the impressive performance of its R&D team. The company is aiming to start Phase II testing on 30 new molecular entities (or NMEs) and product extensions in 2016 and 2017, and start Phase III work on 20 NMEs and extensions during the period.

The stellar development work of recent years is finally expected to begin to pay off from 2016, and an 11% earnings rise is currently forecasted for next year. I believe a subsequent P/E rating of 15.8 times is great value given GlaxoSmithKline’s vastly-improved earnings outlook, particularly as global healthcare investment should keep on surging.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

My £3 a day passive income plan for 2025

Christopher Ruane walks through his plan for next year and beyond of squirreling away and investing a few pounds a…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Can the FTSE 250’s Raspberry Pi boost my portfolio over the next decade?

This British technology stock in the FTSE 250 has exploded onto the London stock market and right now its future…

Read more »

Investing Articles

Does acquiring Direct Line make Aviva shares a buy?

A big acquisition should give Aviva greater scale and profitability, increasing the value of its shares. But is it an…

Read more »

Investing Articles

After a 25% decline in 2024, this FTSE 250 stock is top of my buy list for the New Year

Stephen Wright’s top investment idea is a FTSE 250 stock that’s down 25% this year in an industry that’s under…

Read more »

The words "what's your plan for retirement" written on chalkboard on pavement somewhere in London
Retirement Articles

After a 20% gain in 2024, here’s how I’ll be investing my Stocks and Shares ISA and SIPP in 2025

Edward Sheldon is saving for retirement in a Stocks and Shares ISA and pension. Here’s how he’ll be investing in…

Read more »

Investing Articles

2 S&P 500 funds to consider for huge profits in 2025!

Are you optimistic about the S&P 500's prospects in the New Year? These quality exchange-traded funds (ETFs) could be worth…

Read more »

Investing Articles

A cheap FTSE 100 share that’s tipped to rebound sharply in 2025!

Recent price weakness means this FTSE share now offers stunning all-round value. I think it could experience a strong recovery…

Read more »

Light bulb with growing tree.
Investing Articles

2 sinking FTSE 100 shares I think could rebound in 2025!

Warren Buffett loves buying beaten-down stocks in anticipation of a price recovery. Here are two from the FTSE 100 that've…

Read more »